Dr Paul W. Tebbey is a pharmaceutical development strategy leader with 30 years of healthcare and management experience across the biotechnology and biodefense sectors at companies such as Elusys Therapeutics, Nighthawk Biosciences, Abbvie, Baxter, Johnson & Johnson and Pfizer. Dr Tebbey’s research, development and commercial launch experiences include novel monoclonal antibodies (STELARA® first-in-IL-12/23 class, REMICADE® & HUMIRA® anti-TNF mAbs), complex vaccines (PREVNAR® novel conjugated vaccine, influenza and respiratory syncytial virus), biosimilars as well as targeted oncolytic small molecules (VENCLEXTA®). Dr Tebbey received a Ph.D., in Microbiology and Immunology from East Carolina University School of Medicine as well as an MBA in Marketing from Rochester Institute of Technology. Dr Tebbey’s publications include over 45 peer-reviewed articles that span immunology, infectious diseases, clinical trial design and pharmaceutical strategy planning and brand success.
Mr. Paul Tebbey, NightHawk Biosciences, Inc.
Chief Operating Officer
